Press Releases - Archive



Shareholder Tools


 
Press Releases - Archive
Date Title and Summary View
Sep 15, 2015 SOUTH SAN FRANCISCO, Calif., Sept. 15, 2015 (GLOBE NEWSWIRE) -- Achaogen, Inc. (NASDAQ:AKAO), a clinical-stage biopharmaceutical company developing novel antibacterials to treat multi-drug resistant (MDR) gram-negative infections, today announced upcoming presentations of data from its lead program, plazomicin, at the Interscience Conference of Ant...
Aug 19, 2015 SOUTH SAN FRANCISCO, Calif., Aug. 19, 2015 (GLOBE NEWSWIRE) -- Achaogen, Inc. (NASDAQ:AKAO), a clinical-stage biopharmaceutical company developing novel antibacterials to treat multi-drug resistant (MDR) gram-negative infections, today announced the appointment of Mr. Blake Wise as its Chief Operating Officer, effective October 1st, 2015. "...
Aug 10, 2015 SOUTH SAN FRANCISCO, Calif., Aug. 10, 2015 (GLOBE NEWSWIRE) -- Achaogen, Inc. (NASDAQ:AKAO), a clinical-stage biopharmaceutical company developing novel antibacterials to treat multi-drug resistant (MDR) gram-negative infections, today reported financial results for the second quarter ended June 30, 2015. "I am pleased with the progress achieve...
Aug 5, 2015 SOUTH SAN FRANCISCO, Calif., Aug. 5, 2015 (GLOBE NEWSWIRE) -- Achaogen, Inc. (NASDAQ:AKAO), a clinical-stage biopharmaceutical company developing novel antibacterials to treat multi-drug resistant (MDR) gram-negative infections, announced today that it will present at the 2015 Wedbush PacGrow Healthcare Conference. Kenneth Hillan, Chief Executive O...
Jul 21, 2015 SOUTH SAN FRANCISCO, Calif., July 21, 2015 (GLOBE NEWSWIRE) -- Achaogen, Inc. (NASDAQ:AKAO), a clinical-stage biopharmaceutical company developing novel antibacterials to treat multi-drug resistant (MDR) gram-negative infections, today announced that on July 17, 2015, the compensation committee of the Company's board of directors granted 10 new emp...
Jul 16, 2015 SOUTH SAN FRANCISCO, July 16, 2015 (GLOBE NEWSWIRE) -- Achaogen, Inc. (NASDAQ:AKAO), a clinical-stage biopharmaceutical company developing novel antibacterials to treat multi-drug resistant (MDR) gram-negative infections, announced today it has been awarded a contract for $1.5 million over the next year, with additional funding up to $3.0 million a...
Jul 1, 2015 SOUTH SAN FRANCISCO, Calif., July 1, 2015 (GLOBE NEWSWIRE) -- Achaogen, Inc. (NASDAQ:AKAO), a clinical-stage biopharmaceutical company developing novel antibacterials to treat multi-drug resistant (MDR) gram-negative infections, announced today that it will present at the Cantor Fitzgerald Inaugural Healthcare Conference in New York, NY. Dr. Ian Fr...
Jun 15, 2015 SOUTH SAN FRANCISCO, Calif., June 15, 2015 (GLOBE NEWSWIRE) -- Achaogen, Inc. (Nasdaq:AKAO), a clinical-stage biopharmaceutical company developing novel antibacterials to treat multi-drug resistant (MDR) gram-negative infections, today announced that Dr. Kenneth Hillan, Chief Executive Officer, has accepted invitations to participate and present at...
Jun 11, 2015 SOUTH SAN FRANCISCO, Calif., June 11, 2015 (GLOBE NEWSWIRE) -- Achaogen, Inc. (Nasdaq:AKAO), a clinical-stage biopharmaceutical company developing novel antibacterials to treat multi-drug resistant (MDR) gram-negative infections, announced today the appointment of Mr. Greg Stea to its Board of Directors as a Class II director. In conjunction with t...
May 11, 2015 SOUTH SAN FRANCISCO, May 11, 2015 (GLOBE NEWSWIRE) -- Achaogen, Inc. (Nasdaq:AKAO), a clinical-stage biopharmaceutical company developing novel antibacterials to treat multi-drug resistant (MDR) gram-negative infections, today reported an update of its Phase 3 plazomicin clinical programs as well as financial results for the quarter ended March 31,...
Page: FirstPrevious ...
12
... NextLast
= add release to Briefcase